Registration opens for the 2026 virtual summit addressing critical challenges in quality assurance, regulatory compliance and digital transformation. The three-day programme brings together industry leaders to explore environmental monitoring for advanced therapies, sustainable endotoxin testing, evolving nitrosamine requirements, reference standards in the GLP-1 era and the automation technologies reshaping pharmaceutical manufacturing.
With registration now open and the live stream just over five weeks away, The Future of Bio/Pharmaceutical Analysis Virtual Summit returns on 23, 24 and 25 June 2026 for three days of expert-led debate on the issues defining the next era of pharma. Across nine panel sessions, the agenda moves from the lab floor to the regulatory front line and on to the AI-enabled facilities reshaping the industry.
Key topics on the agenda
This year’s programme spans the modernisation of environmental monitoring for advanced therapies, the shift to sustainable, non-animal endotoxin testing, state-of-the-art contamination control, evolving nitrosamine requirements, reference standards in the GLP-1 era, US and European regulatory change, and the digital, AI and automation technologies redrawing the biopharma manufacturing map.
Day 1 — Tuesday 23 June: rethinking QA/QC
The summit opens with a deep dive into environmental monitoring, where Dr. Michael J. Miller, President of Microbiology Consultants, LLC, sets out how traditional EM practices must adapt to keep pace with biologics, cell and gene therapies. Session two turns to endotoxin testing and the practicalities of switching to non-animal reagents without compromising on speed, cost or compliance. The day closes with contamination control, where Vanessa Vasadi Figueroa (VVF Science), Mark Hallworth (Particle Measuring Systems) and Hayden Skalski (Veolia) examine cleanroom design, post-shutdown risk and detection of challenging contaminants.
Day 2 — Wednesday 24 June: navigating regulatory change
Day two opens with the long-running nitrosamine challenge. Andrew Teasdale (ATCMC Solutions), Malcolm Rossi (Novartis Nitrosamine Task Force), Dr. Archana Bahuguna and Mayank Bhanti, Senior Director at USP, unpack the latest FDA testing deadlines, NDSRI control strategies and how to staff cross-functional teams for success. Attention then shifts to quality control and reference standards in the GLP-1 era, before a closing session on regulatory disruption — covering the next generation of FDA user fee agreements and Europe’s drive to sharpen its competitive edge.
Day 3 — Thursday 25 June: digital, AI and automation
The final day spotlights pharma’s digital transformation. Doris Lacej (Profarma sha), Dr. Raminderpal Singh, Global Head of AI and GenAI Practice at 20/15 Visioneers, and Professor Ziyaur Rahman (Texas A&M University) open with strategic approaches to digitalisation across the manufacturing value chain. Session two, featuring Dr. Sulaf Assi (Liverpool John Moores University) and Professor Vasiliki Kalodimou (Iaso), looks at where AI is already moving the needle on yield analytics and reliability. The summit closes with a session on robotics and the journey towards ‘lights-out’ manufacturing facilities.
Secure your place
Registration is complimentary but places are limited. Join QA/QC, regulatory, manufacturing and analytical development leaders from across the global biopharma industry for three days of practical insight, peer debate and forward-looking strategy. Register now for The Future of Bio/Pharmaceutical Analysis 2026.
No comments yet